RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA
Clinical trials for RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to wipe out Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests a combination of two drugs, acalabrutinib and venetoclax, in people whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has come back or stopped responding to treatment. The goal is to see if this combo can reduce cancer cells to undetect…
Matched conditions: RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 17, 2026 03:58 UTC
-
New drug Q702 aims to boost immune system against blood cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called Q702 in people with certain blood cancers or related diseases that have not responded to other treatments. The drug works by helping the immune system attack cancer cells and supporting normal blood cell production. The study will ch…
Matched conditions: RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 17, 2026 03:53 UTC
-
New hope for Hard-to-Treat blood cancers: targeted drug trial opens
Disease control Recruiting nowThis study tests a drug called mirdametinib in 20 adults whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has returned or stopped responding to treatment. The drug blocks a protein that helps cancer cells grow. The goal is to see if it can shrink tumor…
Matched conditions: RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New combo therapy aims to speed up treatment for blood cancer patients
Disease control Recruiting nowThis study tests whether a faster dose increase of the drug sonrotoclax, given with other medicines, is safe for people with certain blood cancers (CLL, SLL, or mantle cell lymphoma). The cancers may be new, returned, or not responding to treatment. The goal is to see if this qui…
Matched conditions: RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
Engineered immune cells take on tough blood cancers in new trial
Disease control Recruiting nowThis early-phase trial tests a new type of CAR T-cell therapy for people with certain blood cancers (like lymphoma, leukemia) that have returned or not responded to standard treatments. The therapy uses a patient's own immune cells, modified in a lab to target three cancer marker…
Matched conditions: RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
New combo therapy aims to control stubborn leukemia
Disease control Recruiting nowThis study tests whether a combination of two targeted drugs (acalabrutinib and venetoclax) with or without an early dose of a third drug (obinutuzumab) can better control chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that is high-risk, has returned, or s…
Matched conditions: RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 04, 2026 16:25 UTC
-
Engineered immune cells take on tough blood cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new treatment called MC10029, which uses a patient's own immune cells (T cells) that are modified in a lab to attack cancer cells. It is for people with certain types of blood cancers (like lymphoma or leukemia) that have returned or stopped respond…
Matched conditions: RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 04, 2026 16:23 UTC